Skip to main content
Top
Published in: Medical Oncology 10/2014

01-10-2014 | Original Paper

The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia

Authors: Danijela Lekovic, Mirjana Gotic, Natasa Milic, Predrag Miljic, Mirjana Mitrovic, Vladan Cokic, Ivo Elezovic

Published in: Medical Oncology | Issue 10/2014

Login to get access

Abstract

The current widely accepted stratification defined by age and previous thrombosis in patients with essential thrombocythemia (ET) probably deserves deeper analysis. The aim of our study was to identify additional factors at the time of diagnosis, which have an impact on the thrombosis prediction. We conducted a study of 244 consecutive ET patients with median follow-up of 83 months. We analyzed the influence of age, gender, laboratory parameters, history of previous thrombosis, spleen size, JAK2 mutation as well as cardiovascular (CV) risk factors including arterial hypertension, diabetes, active tobacco use and hyperlipidemia in the terms of thrombosis. The most important predictors of thrombosis in multivariate Cox regression model were the presence of CV risk factors (p = 0.004) and previous thrombosis (p = 0.038). Accordingly, we assigned risk scores based on multivariable analysis–derived hazard ratios (HR) to the presence of 1 CV risk factor (HR = 3.5; 1 point), >1 CV risk factors (HR = 8.3; 2 points) and previous thrombosis (HR = 2.0; 1 point). A final three-tiered prognostic model for thrombosis prediction was developed as low (score 0), intermediate (score 1 or 2) and high risk (score 3) (p < 0.001). The hazard of thrombosis was 3.8 % in low-risk group, 16.7 % in the intermediate-risk group and 60 % in the high-risk group (p < 0.001). Patients with thrombotic complications during the follow-up had a significantly shorter survival (p = 0.018). The new score based on CV risk factors and previous thrombotic events allows a better patient selection within prognostic-risk groups and improved identification of the high-risk patients for thrombosis.
Literature
1.
go back to reference Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092–7.PubMedCrossRef Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092–7.PubMedCrossRef
2.
go back to reference Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:171–3.PubMedCrossRef Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:171–3.PubMedCrossRef
3.
go back to reference Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–51.PubMedCrossRef Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–51.PubMedCrossRef
4.
go back to reference Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905–14.PubMedCrossRef Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905–14.PubMedCrossRef
5.
go back to reference Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):285–93.PubMedCrossRef Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):285–93.PubMedCrossRef
6.
go back to reference Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.PubMedCrossRef Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.PubMedCrossRef
7.
go back to reference Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A. Treatment options for essential thrombocythemia and polycythemia vera. Expert Rev Hematol. 2009;2(1):41–55.PubMedCrossRef Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A. Treatment options for essential thrombocythemia and polycythemia vera. Expert Rev Hematol. 2009;2(1):41–55.PubMedCrossRef
8.
go back to reference Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol. 2011;90(6):933–8.PubMedCrossRef Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol. 2011;90(6):933–8.PubMedCrossRef
9.
go back to reference Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24(4):900–3.PubMedCrossRef Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24(4):900–3.PubMedCrossRef
10.
go back to reference Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization- essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33.PubMedCrossRef Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization- essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33.PubMedCrossRef
11.
go back to reference Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9.PubMedCrossRef Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9.PubMedCrossRef
12.
go back to reference Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol. 2014;89(5):542–6.PubMedCrossRef Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol. 2014;89(5):542–6.PubMedCrossRef
13.
go back to reference Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–23.PubMedCrossRef Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–23.PubMedCrossRef
14.
go back to reference Wolansky AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–66.CrossRef Wolansky AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–66.CrossRef
15.
go back to reference Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772–7.PubMedCrossRef Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772–7.PubMedCrossRef
16.
go back to reference Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–4.PubMedCrossRef Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–4.PubMedCrossRef
17.
go back to reference Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840–6.PubMedCrossRef Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840–6.PubMedCrossRef
18.
go back to reference Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84:215–20.PubMedCrossRef Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84:215–20.PubMedCrossRef
19.
go back to reference Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008;22:1494–502.PubMedCrossRef Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008;22:1494–502.PubMedCrossRef
20.
go back to reference Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(6):507–16.PubMedCrossRef Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(6):507–16.PubMedCrossRef
21.
go back to reference Lowe GDO. Common risk factors for both arterial and venous thrombosis. Br J Haematol. 2008;140:488–95.PubMedCrossRef Lowe GDO. Common risk factors for both arterial and venous thrombosis. Br J Haematol. 2008;140:488–95.PubMedCrossRef
22.
go back to reference Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost. 2007;5(Suppl 1):270–5.PubMedCrossRef Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost. 2007;5(Suppl 1):270–5.PubMedCrossRef
23.
go back to reference Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16.PubMed Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16.PubMed
24.
go back to reference Jerjes-Sanchez C. Venous and arterial thrombosis: a continous spectrum of the same disease? Eur Heart J. 2005;26:3–4.PubMedCrossRef Jerjes-Sanchez C. Venous and arterial thrombosis: a continous spectrum of the same disease? Eur Heart J. 2005;26:3–4.PubMedCrossRef
25.
go back to reference Prandoni P, Bilora F, Marchioli A, Bernardi E, Petrobelli F, Lensing AWA, et al. An association between atherosclerosis and venous thromboembolism. N Engl J Med. 2003;348:1435–41.PubMedCrossRef Prandoni P, Bilora F, Marchioli A, Bernardi E, Petrobelli F, Lensing AWA, et al. An association between atherosclerosis and venous thromboembolism. N Engl J Med. 2003;348:1435–41.PubMedCrossRef
26.
go back to reference Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93–102.PubMedCrossRef Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93–102.PubMedCrossRef
27.
28.
go back to reference Bova C, Marchiori A, Noto A, Rossi V, Daniele F, Santoro C, et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost. 2006;96:132–6.PubMed Bova C, Marchiori A, Noto A, Rossi V, Daniele F, Santoro C, et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost. 2006;96:132–6.PubMed
29.
go back to reference Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med. 2012;7(1):9–13.PubMedCrossRef Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med. 2012;7(1):9–13.PubMedCrossRef
30.
go back to reference Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331–5.PubMedCrossRef Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331–5.PubMedCrossRef
31.
go back to reference Masciulli A, Barbui T, Marfisi RM, Cavazzina R, Finazzi G, Lunghi M, et al. How epidemiology of polycythemia vera has changed in the last 10 years: results from the whole prospective cohort of patients in CYTO-PV trial as compared with ECLAP prospective cohort. ASH Annual Meeting Abstracts. 2012;120:1748. Masciulli A, Barbui T, Marfisi RM, Cavazzina R, Finazzi G, Lunghi M, et al. How epidemiology of polycythemia vera has changed in the last 10 years: results from the whole prospective cohort of patients in CYTO-PV trial as compared with ECLAP prospective cohort. ASH Annual Meeting Abstracts. 2012;120:1748.
32.
go back to reference Delluc A, Malécot JM, Kerspern H, Nowak E, Carre JL, Mottier D, Le Gal G, et al. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis. 2012;220(1):184–8.PubMedCrossRef Delluc A, Malécot JM, Kerspern H, Nowak E, Carre JL, Mottier D, Le Gal G, et al. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis. 2012;220(1):184–8.PubMedCrossRef
33.
go back to reference Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Roosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970–5.PubMedCrossRef Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Roosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970–5.PubMedCrossRef
34.
go back to reference Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–61.PubMedCrossRefPubMedCentral Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–61.PubMedCrossRefPubMedCentral
35.
go back to reference Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost. 2009;7:514–20.PubMedCrossRef Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost. 2009;7:514–20.PubMedCrossRef
36.
go back to reference Poredos P, Jezovnik MK. Dyslipidemia, statins, and venous thromboembolisam. Semin Thromb Hemost. 2011;37(8):897–902.PubMedCrossRef Poredos P, Jezovnik MK. Dyslipidemia, statins, and venous thromboembolisam. Semin Thromb Hemost. 2011;37(8):897–902.PubMedCrossRef
37.
go back to reference Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008;4:CD006503. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008;4:CD006503.
38.
go back to reference Tefferi A, Barbui T. Personalized management of essential thrombocythemia—application of recent evidence to clinical practice. Leukemia. 2013;27:1617–20.PubMedCrossRefPubMedCentral Tefferi A, Barbui T. Personalized management of essential thrombocythemia—application of recent evidence to clinical practice. Leukemia. 2013;27:1617–20.PubMedCrossRefPubMedCentral
Metadata
Title
The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia
Authors
Danijela Lekovic
Mirjana Gotic
Natasa Milic
Predrag Miljic
Mirjana Mitrovic
Vladan Cokic
Ivo Elezovic
Publication date
01-10-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 10/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0231-1

Other articles of this Issue 10/2014

Medical Oncology 10/2014 Go to the issue